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ABSTRACT
Objectives: Treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine
(SP) is followed by a sharp rise in the prevalence and density of gametocytes. We did a
randomized trial to determine the effect of treatment of asymptomatic infections with SP or SP
plus one dose of artesunate (SPþAS) on gametocyte carriage.
Design: The study was a three-arm open-label randomized trial. We randomized
asymptomatic carriers of P. falciparum to receive antimalarial treatment or placebo, and
recorded the prevalence and density of gametocytes over the next 2 mo.
Setting: The trial was conducted during the dry (low malaria transmission) season in four rural
villages in Gambia.
Participants: Participants were adults and children aged over 6 mo with asexual P. falciparum
infection and confirmed free of clinical symptoms of malaria over a 2-d screening period.
Interventions: Participants were randomized to receive a single dose of SP or SPþAS or
placebo.
Outcome Measures: The outcome measures were the presence of gametocytes 7 and 56 d
after treatment, and the duration and density of gametocytaemia over 2 mo.
Results: In total, 372 asymptomatic carriers were randomized. Gametocyte prevalence on day
7 was 10.5% in the placebo group, 11.2% in the SP group (risk difference to placebo 0.7%, 95%
confidence interval  7.4% to 8.7%, p ¼ 0.87), and 7.1% in the SPþAS group (risk difference to
placebo 4.1%, 95% confidence interval  3.3% to 12%, p ¼ 0.28). By day 56, gametocyte
prevalence was 13% in the placebo group and 2% in both drug-treated groups. Gametocyte
carriage (the area under the curve of gametocyte density versus time), was reduced by 71% in
the SP group, and by 74% in the SPþAS group, compared to placebo. Gametocyte carriage
varied with age and was greater among children under 15 than among adults.
Conclusions: Treatment of asymptomatic carriers of P. falciparum with SP does not increase
gametocyte carriage or density. Effective treatment of asexual parasitaemia in the dry season
reduces gametocyte carriage to very low levels after 4 wk.
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PLoS CLINICAL TRIALSINTRODUCTION
In sub-Saharan Africa, malaria caused by Plasmodium falcipa-
rum is responsible for 300 million clinical cases and up to 1
million deaths annually, mainly among children under 5 y of
age. Treatment of P. falciparum malaria with commonly used
antimalarial drugs such as chloroquine or sulfadoxine-
pyrimethamine (SP) is followed by a marked increase in the
density of gametocytes, the parasite stage that infects
mosquitoes [1–5]. This density increase may reﬂect drug-
induced release of sequestered gametocytes into the periph-
eral circulation after treatment with SP but could also be
explained by the natural wave of gametocytaemia in an acute
infection, against which antimalarial drugs have varying
impact [5,6]; this issue has not been investigated experimen-
tally. Drug-induced release of gametocytes could enhance
transmission of resistant parasites and would argue against
the use of SP, especially for intermittent preventive treat-
ment [7,8]. The effects of antimalarial drugs on gametocytes
and their infectiousness to vector mosquitoes have been
mainly studied either in vitro or in clinical cases [1–5,9–14],
and so the effect of antimalarial treatment on gametocyte
carriage has not been evaluated in a randomized placebo-
controlled study. Treatment with artemisinin derivatives in
combination with other drugs results in lower gametocyte
carriage rates and density, and reduced infectiousness of
treated individuals compared to non-artemisinin regimens
[3,4,9,11,14,15]. These properties suggest artemisinin-based
combination therapies could be effective tools for intermit-
tent treatment strategies (e.g., [16]), but few data exist on the
dynamics of gametocytaemia, both with and without drug
treatment, in individuals who are infected but without
symptoms [17]. To investigate this, we randomized individuals
who had P. falciparum infection without clinical symptoms of
malaria to treatment with SP, a combination of SP plus one
dose of artesunate (SPþAS), or placebo, to determine the
effects of treatment on gametocyte prevalence, duration of
gametocyte carriage, and gametocyte density.
METHODS
Participants
The climate in Gambia is characterised by a long dry season
from mid-October to mid-June followed by a short rainy
season. Malaria is predominantly caused by P. falciparum, and
occasionally by P. malariae and P. ovale, and transmission is
highly seasonal, with most morbidity due to malaria occur-
ring from September to November [18]. The study was
conducted in four villages located west of Farafenni in the
North Bank Division of Gambia. The total population of the
villages, which are included in the Farafenni Demographic
Surveillance System, was 2,300. Meetings were held in the
villages to explain the objectives of the study and to seek the
consent of the community leaders and villagers. All residents
aged 6 mo and above were identiﬁed using the Demographic
Surveillance System database and screened in order of
Demographic Surveillance System number for participation
if they, or their accompanying parents or guardians in the
case of children under 16 y, gave written consent. Screening
continued until the required quota of eligible participants
was obtained for randomizaton. Gambia Government/Medi-
cal Research Council Joint Ethics Committee approved the
study. Screening took place from May to the end of June in
2001. Eligible participants were asked about symptoms
suggestive of malaria and were clinically examined. Axillary
temperature was measured using a digital thermometer and,
in children 2–9 y, spleen size was determined. Finger prick
blood samples were taken for packed cell volume (PCV)
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Editorial Commentary
Background: During the life cycle of the Plasmodium falciparum malaria
parasite, some parasites differentiate into sexual stages (gametocytes) in
the blood of infected people. Gametocytes are the transmissible stage of
the parasite that can infect the mosquito when it takes a blood meal
from an infected person. In people with clinical signs of malaria,
treatment with commonly used antimalarial drugs such as chloroquine
or sulfadoxine-pyrimethamine is often followed by a rise in the numbers
of gametocytes in the blood, but it is not known to what extent this is
caused by the drugs themselves. The effects of different antimalarial
treatments on gametocytes have generally not been well studied in
trials, and particularly not in individuals who are infected with malaria
but don’t show clinical signs (i.e., asymptomatic carriers). However, it is
important to know the effects of different malaria drugs on gametocytes,
because this will help predict how parasites are likely to evolve resistance
to drugs. In particular, the effects on asymptomatic carriers are
interesting because of the potential benefit of giving preventive
treatments to all children or adults (whether or not they have symptoms)
for malaria control. The trial from Gambia reported here was conducted
in adults and children over 6 mo of age who were infected with P.
falciparum malaria but free from clinical symptoms. Participants were
randomized to receive either sulfadoxine-pyrimethamine, sulfadoxine-
pyrimethamine and artesunate, or placebo. The researchers wanted to
look at the effect of these treatments on numbers of gametocytes in the
participants’ blood samples seven days after treatment (the primary
outcome) and then up to 56 days after treatment.
What this trial shows: Seven days after treatment, the researchers
found that the proportion of participants carrying malaria gametocytes
in the groups treated with sulfadoxine-pyrimethamine or sulfadoxine-
pyrimethamine and artesunate was similar to the proportion in the
placebo group. A secondary objective of the study was to look at overall
gametocyte load over 56 days following treatment, by measuring the
area under the curve plotting gametocyte density against time. For this
secondary objective, the researchers found that gametocyte load was
highest in the placebo group, and substantially lower in the groups
treated with sulfadoxine-pyrimethamine or sulfadoxine-pyrimethamine
and artesunate. Therefore, there was no evidence that treatment with
sulfadoxine-pyrimethamine increased gametocytes in the blood of
children infected with malaria but without symptoms.
Strengths and limitations: In this trial, screening tests to detect malaria
infection and symptoms were done twice prior to enrolling participants
into the trial, with a two-day window between tests. This procedure
increased the chance of detecting individuals with clinical malaria so
they could be excluded from the trial and treated for malaria. The use of
a placebo arm in the trial, which adds to the strength of the study, could
therefore be defended ethically. The conduct of this trial in a region with
seasonal transmission of malaria limits the extent to which the findings
can be generalized to other regions.
Contribution to the evidence: This trial provides data on the extent to
which treatment with sulfadoxine-pyrimethamine or sulfadoxine-pyr-
imethamine and artesunate affects gametocyte levels in people infected
with malaria, but without symptoms. It had previously been thought that
sulfadoxine-pyrimethamine increased gametocyte carriage, but this had
not been formally tested in a placebo-controlled study. The results show
that both treatments reduce overall gametocyte load to very low levels
over a period of 56 days after treatment, as compared to placebo.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.determination and malaria microscopy. Two days later (day 0
[D0]), the results were given to the participants and the
interview and clinical examination repeated for those who
had asexual parasitaemia and had been free of symptoms.
Individuals with at least two asexual parasites per 50 high-
powered ﬁelds (HPFs) (20 asexual parasites per microlitre of
blood) without pyrexia (temperature   37.5 8C) or other
symptoms suggestive of malaria at the ﬁrst and second
screening were enrolled into the study as asymptomatic
malaria cases. The parasitaemia cut-off (20 parasites per
microlitre of blood) was chosen to minimise the risk of
enrolling false positives [19]. Exclusion criteria were preg-
nancy, weight less than 5 kg, symptoms or signs of other
diseases at the ﬁrst and/or second screening, and history of
hypersensitivity to any of the study drugs or their use within
the past 4 wk. Anaemia was not an exclusion criterion, but
participants with PCV less than 33% were given a course of
iron tablets. Chloroquine was the only antimalarial drug
available in the villages and is dispensed by village health
workers, but there was little chloroquine prescription in the
villages at the time of the year that enrolment took place.
Interventions
Participants enrolled were randomized to receive SP alone,
SPþAS, or placebo. Participants who had symptomatic
malaria at screening were not randomized but were treated
with SPþAS and followed up similarly, in order to check that
the normal pattern of gametocyte carriage after treatment in
clinical cases was observed. Open-label SP (Pharmamed,
Zejtun, Malta), artesunate (manufactured by Guilin Pharma-
ceutical Works and supplied by Sanoﬁ, Paris, France), and
calcium (Aegis, Lefkosia, Cyprus) were used.
Objectives
We wanted to determine the effect of treatment with SP
alone and with a single dose of artesunate on gametocyte
.......................................................................................................................................................................................
Table 1. Prevalence of Asexual Parasitaemia and Gametocytes in Children and Adults Who Were Screened
Characteristic Subcategory Prevalence of
Asexual Parasitaemia
Gametocyte
Prevalence
Unadjusted Odds Ratio for
Gametocyte Carriage (95% CI)
p-Value for Gametocyte
Odds Ratio
Gender Male (n ¼ 472) 45% 11% 1
Female (n ¼ 576) 38% 8.5% 0.79 (0.52, 1.2) 0.251
Age Less than 5 y (n ¼ 150) 34% 12% 1
5t o1 5y( n ¼ 458) 61% 14% 1.2 (0.71, 2.2) 0.458
16 to 25 y (n ¼ 129) 46% 7.8% 0.62 (0.27, 1.4) 0.242
Over 25 y (n ¼ 304) 14% 1.6% 0.12 (0.05, 0.34 ,0.0001
Village Alkali Kunda (n ¼ 227) 45% 8.4% 1
Dai Mandinka (n ¼ 127) 44% 7.9% 0.94 (0.42, 2.1) 0.870
Jajari (n ¼ 417) 38% 8.6% 1.0 (0.58, 1.8) 0.909
Yallal (n ¼ 277) 42% 12% 1.5 (0.85, 2.8) 0.157
DOI: 10.1371/journal.pctr.0010020.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. Smoothed Estimate of Gametocyte Prevalence in Relation to Age (in Years) among 1,048 Children and Adults Who Were Screened
Dashed lines indicate 95% CIs.
DOI: 10.1371/journal.pctr.0010020.g001
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Malaria Treatment and Gametocyte Carriagecarriage, in people with P. falciparum infection during the low-
transmission season.
Outcomes
The primary outcomes were gametocyte prevalence and
density on D7, and secondary outcomes were gametocyte
prevalence on D56 after treatment, and gametocyte carriage,
deﬁned as the area under the curve (AUC) of gametocyte
density against time. Participants were visited at home by
ﬁeld workers on D3, D7, D14, D28, and D56 post-treatment to
check that the person was well, to record self-reported
adverse events, and to collect ﬁnger prick blood for micro-
scopy. The study was not blinded, but ﬁeld workers and
Figure 2. Trial Profile
DOI: 10.1371/journal.pctr.0010020.g002
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Table 2. Baseline Characteristics of Trial Participants and Clinical Cases
Characteristic Treatment Group Clinical Cases Receiving
SPþAS (n ¼ 39) SP (n ¼ 124) SPþAS (n ¼ 124) Placebo (n ¼ 124)
Gender ratio (male:female) 60:64 65:59 62:62 17:22
Village Alkali Kunda 34 34 34 5
Dai Mandinka 17 16 16 4
Jajari 43 44 44 16
Yallal 30 30 30 14
Median age in years (range) 10 (0.7, 72) 11 (0.9, 72) 11 (1.0, 56) 5 (0.7, 45)
Mean PCV (standard deviation) 34.0 (4.0) 33.5 (3.8) 33.3 (3.7) 32.3 (3.4)
Anaemia, PCV , 33%, n (%) 36 (29%) 40 (33%) 47 (38%) 17 (44%)
Asexual parasite density, geometric mean (range) 277 (5, 19,700) 270 (5, 20,800) 305 (3, 7,000) 706 (10, 32,560)
Gametocyte positive, n (%) 30 (24%) 20 (16%) 31 (25%) 9 (23%)
DOI: 10.1371/journal.pctr.0010020.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Malaria Treatment and Gametocyte Carriagelaboratory assistants responsible for microscopy did not have
access to treatment allocation data and therefore were likely
to be unaware of the treatment received by participants. Two
thick blood ﬁlms were prepared from each individual, dried
overnight, and stained with Giemsa, and 200 HPFs were
examined independently by two microscopists for asexual
and sexual stage parasites. Where there was a discrepancy the
slide was read a third time, by another microscopist. During
screening, one blood ﬁlm was stained with Field’s stain, and
50 HPFs were examined to identify infected individuals for
enrolment. PCV was determined by collecting ﬁnger prick
blood samples into heparinised capillary tubes and spinning
them using a micro-haematocrit centrifuge (Hawksley, Lanc-
ing, England).
Sample Size
The primary endpoint was gametocyte prevalence on D7.
Assuming a gametocyte rate in the placebo group of 20%, a
sample size of 120 individuals per group would allow over
80% power to detect an increase to 40% in the SP-alone
group and a decrease to 5% or less in the SPþAS group,
allowing for 10% drop-out and using a signiﬁcance level of
0.025 (to allow for two primary comparisons with an overall
type 1 error rate of 0.05).
Randomization
The randomization sequence was generated in Stata (Stata-
corp, College Station, Texas, United States) using restricted
randomization with a block size of 12. Treatment allocation
was determined by opening pre-prepared numbered opaque
randomization envelopes in sequence by a study nurse who
took no part in participant selection or evaluation, but who
acted as the drug dispenser throughout the trial. SP was
administered as 25 mg/kg sulfadoxine/1.25 mg/kg pyrimeth-
amine for children under 50 kg, while adults and children
weighing 50 kg or more were given three tablets (each tablet
contained 500 mg of sulfadoxine and 25 mg of pyrimeth-
amine) . In the SPþAS group, artesunate was given at the same
time as SP at a dose of 200 mg (four tablets at 50 mg) for
adults and for children weighing 50 kg or more, while
children under 50 kg received 4 mg/kg body weight. Calcium
tablets were given as placebo. Children were observed for 1 h
after treatment to ensure that the drug was not vomited, and
treatment was repeated in those who vomited the ﬁrst dose.
Treatment failures in the SP and SPþAS groups were to
receive rescue medication with quinine while those in the
placebo group were to be rescued with chloroquine and SP
(which is highly effective in Gambia [3]).
Statistical Methods
Data were double entered and validated. Analysis was done
using Stata. Fractional polynomial logistic regression [20] was
used to obtain a smoothed estimate of the proportion of
gametocyte carriers as a function of age. Parasite density was
calculated by assuming one parasite per HPF to be equivalent
to 500 parasites per microlitre blood [21]. Primary analysis
was by intention to treat. Gametocyte prevalence was
compared using the chi-squared test and gametocyte densities
using one-way analysis of variance on log-transformed
densities. p-Values are two-sided. We summarised the
information on gametocyte carriage by calculating the AUC
of the gametocyte density against time, a measure of trans-
Figure 3. Prevalence of Asexual Parasitaemia and Gametocytes after
Treatment
(A) Prevalence of asexual parasitaemia over the 2 mo following treatment.
The profile for the 39 clinical cases, who were treated with SPþAS, is also
shown.
(B) Prevalence of gametocytes.
(C) Prevalence of gametocytes in the subset of participants who were
gametocyte negative on D0.
DOI: 10.1371/journal.pctr.0010020.g003
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Malaria Treatment and Gametocyte Carriagemission potential. This is a weighted sum of the gametocyte
densities, with weights proportional to the difference in time
between adjacent sampling points. Individuals with missing
data were included in the analysis, with the AUC weighted
according to the number of non-missing sampling points.
Similarly, an AUC was calculated for the binary variable
(gametocyte positive, 1, or negative, 0) against time. The mean
of this AUC is the area under the curve of the proportion
positive plotted against time, and is a measure of the average
duration of gametocyte carriage. We compared the AUC
between treatment groups using the Kruskal-Wallis test and
between age groups using a non-parametric test for trend
[22]; both tests were adjusted for tied values.
RESULTS
Recruitment and Participant Flow
A total of 1,184 participants were screened in May and June
2001. Of these, 136 were excluded (78 had missing para-
sitological data, ﬁnger prick samples were not collected from
19 women who were pregnant, and 39 participants had
clinical P. falciparum malaria). Of the remaining 1,048
participants, representing 46% (1,048/2,300) of the popula-
tion of the study villages, 99 (9.4%) had gametocytaemia with
a geometric mean density of 6.1 (95% conﬁdence interval [CI]
5.0 to 7.5) gametocytes per microlitre. A total of 616/1,048
(59%) did not have detectable asexual parasitaemia, and most
of these (97.4%) were gametocyte negative. Gametocyte
prevalence was high among children under 15 y and then
decreased with increasing age, and gametocyte prevalence
was similar in males and females and in each of the four
villages (Table 1). Gametocyte prevalence in relation to age is
shown in Figure 1.
Out of 1,148 screened individuals, 372 had asymptomatic P.
falciparum infection above 20 parasites per microlitre and
were enrolled into the trial (Figure 2). In addition, 39 clinical
cases that were not randomized were treated with SPþAS and
followed up. The randomized groups were similar in
demographic and clinical characteristics and asexual parasite
density and gametocyte rates at baseline (Table 2). On
completion of follow-up (D56), parasitological data were
available for 339 (91%) individuals in the trial. During the 56
d of follow-up there were no cases of clinical malaria and no
adverse events were reported in any trial participants.
Outcomes and Estimation: The Effect of Treatment on
Asexual Parasitaemia and Gametocytaemia
Asexual parasite clearance was similar in the SP and SPþAS
groups (Figure 3A). Gametocyte rates in the SP and placebo
groups were similar on D3, D7, and D14. On D7, the
prevalence of gametocyte carriage was 10.5% in the placebo
group and 11.2% in the SP group (risk difference 0.7%, 95%
CI  7.4% to 8.7%, p ¼ 0.87), and 7.1% in the SPþAS group
(difference between SPþAS and SP groups, 4.1%, 95%CI
 3.3% to 12%, p ¼ 0.28). Gametocyte prevalence showed a
steady decline in the active drug treatment groups, and by
D28, gametocyte prevalence was less than 3% in the SP and
SPþAS groups (Figure 3B). In contrast, gametocyte prevalence
in the clinical cases had increased by D3. The AUC index of
gametocyte carriage (Table 3) was 62 in the placebo group;
treatment with SP reduced this index to 18 (a 71% reduction,
p , 0.001, Kruskal-Wallis test), and addition of AS reduced
this index to 16 (a 74% reduction from the value in the
placebo group, p , 0.001, and only slightly lower than the SP
group, p ¼ 0.02). In the clinical cases, the AUC gametocyte
index was 147, signiﬁcantly greater than the asymptomatic
group treated with the same drug regimen (p ¼ 0.02) but not
signiﬁcantly different from the placebo group (p ¼ 0.32).
Among the 290 randomized participants who were game-
tocyte negative at enrolment, gametocyte prevalences on D3,
D7, and D14 were similar in the SP and placebo groups
(Figure 3C), suggesting SP has no effect on the release of
tissue-sequestered gametocytes into the peripheral circula-
tion.
Mean AUC gametocyte index varied with age and was
greatest among children under 15 y; this pattern was
associated with greater asexual parasite densities in this age
group at enrolment (Table 4). The average gametocyte AUC
index for the population of the study villages—obtained as a
weighted mean of the age-speciﬁc gametocyte AUC values for
the placebo group, taking account of the age distribution and
asexual parasite prevalences in Table 1 and assuming
negligible gametocyte carriage among asexual negative
individuals—was 25; if gametocyte carriage among adults is
ignored, this mean value becomes 23, indicating that
gametocyte carriage among adults contributes only a small
percentage to the overall value.
DISCUSSION
Interpretation
In areas of seasonal malaria transmission, intermittent
treatment of children with antimalarial drugs or some form
of chemoprophylaxis may have a role in malaria prevention
[8,16,18,23]. Mass treatment (single or repeated administra-
tions of antimalarial drugs to all members of the population,
usually during the dry season, in an attempt to reduce
transmission) has not proved a useful strategy [24] but might
.......................................................................................................................................................................................
Table 3. Effect of Treatment on Gametocyte Carriage
Measure Treatment Kruskal-Wallis Test p-Value
SP (n ¼ 124) SPþAS (n ¼ 124) Placebo (n ¼ 124)
Mean AUC of gametocyte density per microlitre versus time
a 18 16 62 ,0.001
Mean duration of gametocyte carriage (days) 3.3 2.1 8.0 ,0.001
Number (%) of sampling times when gametocyte positive 59/600 (9.8%) 33/570 (5.8%) 102/570 (17.9%)
Geometric mean gametocyte density per microlitre on
days when gametocytes were detected
4.5 4.4 5.9
aIn the clinical cases over 56 d, mean gametocyte AUC was 147.
DOI: 10.1371/journal.pctr.0010020.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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be effective in areas where there is a very short transmission
season [25]. In recent randomized trials of these approaches,
SP has been used alone or in combination with artesunate.
We investigated the effects of antimalarial treatment with
these drugs on circulating gametocytes in volunteers with
asymptomatic P. falciparum infection, and we found no
evidence that SP treatment enhances emergence of game-
tocytes into the peripheral blood, but rather that, during the
dry season, effective treatment with SP or SPþAS virtually
eliminates gametocyte carriage over time. Gametocyte car-
riage was not signiﬁcantly reduced further by the addition of
a single dose of artesunate; three doses may be more effective
[3]. Administration of antimalarial drugs through intermit-
tent or mass treatment strategies carries the risk that
selection for drug-resistant genotypes will be increased. This
risk needs careful evaluation, but our study shows that
preventive treatment of asymptomatic individuals with SP
alone or in combination with artesunate in the dry season
leads to a substantial reduction in gametocyte carriage and
therefore may reduce transmission from treated individuals.
In our study, the AUC index of gametocyte carriage was
substantially higher in children under 15 y of age than in
adults. This ﬁnding is compatible with acquisition of anti-
gametocyte immunity [17] but could be explained by greater
ability to control asexual parasitaemia in adults [26]. Children
under 15 y carry gametocytes for longer and at higher
densities than adults, but other factors such as differences in
the degree of exposure to biting mosquitoes and the greater
skin area of adults make it difﬁcult to estimate the relative
contribution of adults and children to transmission.
Generalisability
Our study, conducted in the dry season in asymptomatic
carriers, does not rule out the possibility that in acute clinical
cases, with much greater parasite densities, treatment with SP
causes some release of sequestered gametocytes, but our data
are compatible with the explanation suggested by Butcher [6],
that the rise in gametocytaemia observed immediately after
SP treatment in clinical cases [3–5,27] is most likely explained
by the natural wave of gametocytaemia in an acute infection,
against which SP has no impact, but which is time-limited due
to the eradication of the asexual parasite biomass.
Overall Evidence
Treatment reduces gametocyte carriage to very low levels
over a period of 1 mo; mass drug administration of SPþAS in
the study area in June 1999 did not reduce overall malaria
incidence despite achieving relatively high coverage [24], and
while low levels of gametocyte carriage may be sufﬁcient to
sustain transmission, earlier treatment might have had a
greater impact.
SUPPORTING INFORMATION
CONSORT Checklist
Found at DOI: 10.1371/journal.pctr.0010020.sd001 (48 KB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010020.sd002 (229 KB DOC).
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